Eli Lilly’s next-generation obesity franchise advanced further with new Phase 3 topline data for retatrutide, reinforcing the company’s competitive positioning versus both GLP-1 and dual-agonist rivals. Lilly reported that in the Triumph-1 Phase 3 trial, weekly retatrutide met primary and key secondary endpoints across tested doses, delivering average body-weight reductions that reached 28.3% at the highest dose. The trial also showed measurable improvements in cardiovascular risk factors, while a meaningful share of patients reported gastrointestinal side effects such as nausea or diarrhea. Elsewhere, another report framed the same Phase 3 readout as bringing retatrutide “one step closer” to a potential FDA approval path, with side-effect frequency and severity presented as part of the benefit-risk discussion. With follow-on presentations scheduled for the next major diabetes meeting, Lilly is setting up continued regulatory and commercial positioning around magnitude of weight loss and tolerability. Overall, the obesity pipeline shift is now focused on differentiating efficacy ceilings and managing adverse-event profiles at scale, as Lilly aims to keep retatrutide at the top of late-stage comparators.